John Patrick Tejada, MD
Pulmonary Disease · Greenwood, SCNPI 1801104559
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,317 of the $16,074 with a category attached, or 64.2%. 36 manufacturers reported payments, led by Intuitive Surgical at 34.8% of the total. 2025 is the largest year on record at $7,410, 6.2 times the $1,204 reported in 2019.
Across 549 payments — averaging $29.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$2K
- Actelion Pharmaceuticals US, Inc.$1K
- AstraZeneca$1K
- Sanofi$910
- United Therapeutics Corporation$876
- plus $4K from 30 others
What the payments were for
- Food & beverage$10,31764%
- Education$5,75736%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $5,595 |
| GSK | 123 | $1,818 |
| Actelion Pharmaceuticals US, Inc. | 71 | $1,330 |
| AstraZeneca(2 entities) | 59 | $1,175 |
| Sanofi | 35 | $910 |
| United Therapeutics Corporation | 38 | $876 |
| Boehringer Ingelheim | 49 | $846 |
| Insmed, Inc. | 38 | $655 |
| Mylan Specialty L.p. | 23 | $443 |
| Gilead | 17 | $377 |
| Regeneron Healthcare Solutions, Inc. | 11 | $246 |
| Merck | 11 | $238 |
| Verona Pharma, Inc. | 10 | $198 |
| Inari Medical, Inc. | 1 | $185 |
| Amgen | 9 | $156 |
| Bayer | 6 | $128 |
| Baxter Healthcare | 3 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $106 |
| Genentech USA, Inc. | 5 | $86 |
| Electromed, Inc. | 5 | $79 |
| ANI Pharmaceuticals, Inc. | 3 | $65 |
| Philips North America LLC | 3 | $62 |
| Advanced Respiratory, Inc | 3 | $55 |
| Viatris Specialty LLC | 2 | $47 |
| Harmony Biosciences LLC | 2 | $45 |
| Grifols USA, LLC | 2 | $43 |
| Resmed Corp | 1 | $33 |
| Liquidia Technologies, Inc. | 1 | $25 |
| Fisher & Paykel Healthcare Inc | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Pfizer | 1 | $17 |
| Medtronic | 1 | $15 |
| CSL Behring | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,074 in reported general payments places this provider in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 80 | $1,938,466 |
| OpsumitMacitentan | 130 | $1,618,471 |
| Orenitram ErTreprostinil Diolamine | 36 | $493,218 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 316 | $247,728 |
| AdempasRiociguat | 13 | $183,697 |
| LetairisAmbrisentan | 12 | $155,767 |
| OfevNintedanib Esylate | 28 | $152,537 |
| Dupixent SyringeDupilumab | 34 | $147,260 |
| Dupixent PenDupilumab | 31 | $113,243 |
| Pirfenidone | 17 | $71,885 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 111 | $56,420 |
| Breo ElliptaFluticasone/Vilanterol | 123 | $48,825 |
| Ambrisentan | 15 | $42,750 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $36,209 |
| Incruse ElliptaUmeclidinium Bromide | 72 | $29,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,330 | $3,556,937210 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,818 | $388,728644 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $846 | $197,967101 claims |
| BayerAdempas | $128 | $183,69713 claims |
| GileadLetairis | $377 | $155,76712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,175 | $49,291102 claims |
| PfizerEliquis | $17 | $15,00116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Greenwood
- Leonard LimGreenwood$11K
- Raymond LewisGreenwood$10K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.